News

Apomorphine as Steady Infusion of Benefit in Advanced Parkinson’s

Two years of continuous treatment with apomorphine as an under-the-skin infusion safely preserved quality of life and effectively eased motor fluctuations in people with advanced Parkinson’s disease, according to a single-center, real-life study in France. Notably, patients with poor life quality before starting with continuous apomorphine were more likely to improve in…

Caraway, AbbVie Ink Deal to Develop TMEM175-targeting Therapies

Caraway Therapeutics is partnering with AbbVie to develop and market Caraway’s small molecule therapies targeting TMEM175, a potassium ion channel implicated in Parkinson’s disease and other neurodegenerative disorders. TMEM175 is present in lysosomes — tiny compartments in cells containing enzymes that break down unwanted cell parts, digesting and…

FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment

The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add a Parkinson’s disease symptom assessment tool to the company’s clinical research-focused smartwatch. In its response letter, the FDA said there was not enough evidence that the criteria evaluated…

‘Robust’ Genetic Patient Data Open to Researchers via Fox DEN

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe are opening “robust” genetic data to researchers worldwide that could help in identifying markers of treatment response and disease progression, and ultimately may lead to better therapies for Parkinson’s disease. These new and de-identified (for privacy)…

Senses Related to Smell May Be Predictor of Parkinson’s

A chemical sense related to smell, called the trigeminal system, may help researchers understand which people who lose their sense of smell will later develop Parkinson’s disease. Parkinson Canada is supporting this research through a $45,000, yearlong grant, given to Johannes Frasnelli, PhD, of l’Université de Québec á…